You are here

  • Home
  • Archive
  • Volume 17, Issue 1
  • Similar rates of relapse and time to return to normal activity with 2 or 5 days of systemic corticosteroids after asthma exacerbation but study confirmation of equivalence would require further study

Article Text

Article menu
Download PDFPDF
Therapeutics
Randomised controlled trial
Similar rates of relapse and time to return to normal activity with 2 or 5 days of systemic corticosteroids after asthma exacerbation but study confirmation of equivalence would require further study
  1. Brian H Rowe
  1. Emergency Medicine, University of Alberta, Edmonton, Canada
  1. Correspondence to Brian H Rowe
    Emergency Medicine, University of Alberta, 1G1.43 WMC, 8440-112 Street NW, Edmonton, AB T6G 2B7, Canada; Brian.Rowe{at}ualberta.ca

https://doi.org/10.1136/ebmed.2011.100257

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Commentary on: Kravitz J, Dominici P, Ufberg J, et al. Two days of dexamethasone versus 5 days of prednisone in the treatment of acute asthma: a randomized controlled trial. Ann Emerg Med 2011;58:200–4.OpenUrlCrossRefPubMed

    Context

    Asthma is common and flare-ups associated with exposure to a variety of triggers may result in emergency department (ED) visits, school and work absenteeism, hospitalisations and significant healthcare costs. The majority of adult patients presenting with acute asthma are discharged home following management in the ED. Many national and international guidelines have been developed on this topic.1 In the outpatient setting, care is focused on the use of systemic (SC) and inhaled corticosteroid (ICS) agents to regain asthma control. While prednisone is the most common SC used, there has been an interest in reducing the duration of treatment using agents with longer half life such as …

    View Full Text

    Footnotes

    • Competing interests BHR has received research funding from GSK and MedImmune Inc in the past 2 years. BHR is supported by a Tier I Canada Research Chair in Evidence Based Emergency Medicine from the Canadian Institutes of Health Research (Ottawa, ON).